Literature DB >> 23224211

[Cytokine determination from vitreous samples in retinal vascular diseases].

M Pfister1, F H Koch, J Cinatl, F Rothweiler, R Schubert, P Singh, H Ackermann, M J Koss.   

Abstract

PURPOSE: The aim of this study was to determine cytokine levels from vitreous samples of treatment-naive patients with diabetic retinopathy (DRP), retinal vein occlusion (RVO) and exudative age-related macular degeneration (ARMD).
METHODS: In this study 187 patients (median age 67 years, 101 males) were treated with a combined drug therapy including a 23-gauge core vitrectomy. Interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and intravitreal vascular endothelial growth factor (VEGF-A) levels were determined a using cytometric bead assay (CBA) and compared to those of the control group.
RESULTS: Compared to the control group all diseases had significantly elevated cytokine levels, except VEGF in ARMD. In DRP samples of patients with diffuse diabetic macula edema (DME) higher VEGF-A and MCP-1 levels were found than in patients with focal DME. Ischemic DRP had higher VEGF levels than non-ischemic DRP. All measured cytokines were significantly higher in central retinal vein occlusion (CRVO) than in branch retinal vein occlusion (BRVO).
CONCLUSIONS: Differences in intravitreal cytokine levels in DRP, RVO and ARMD could be demonstrated. The knowledge of depicted specific characteristic dysregulation of cytokines could allow more targeted future therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23224211     DOI: 10.1007/s00347-012-2719-4

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  33 in total

1.  Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment.

Authors:  Shuzo Kaneda; Dai Miyazaki; Shin-ichi Sasaki; Keiko Yakura; Yuki Terasaka; Ken-ichiro Miyake; Yoshifumi Ikeda; Taisaku Funakoshi; Takashi Baba; Atsushi Yamasaki; Yoshitsugu Inoue
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-06       Impact factor: 4.799

2.  A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.

Authors:  Ingrid U Scott; Allison R Edwards; Roy W Beck; Neil M Bressler; Clement K Chan; Michael J Elman; Scott M Friedman; Craig Michael Greven; Raj K Maturi; Dante J Pieramici; Michel Shami; Lawrence J Singerman; Cynthia R Stockdale
Journal:  Ophthalmology       Date:  2007-08-15       Impact factor: 12.079

3.  Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion.

Authors:  H Noma; H Funatsu; M Yamasaki; H Tsukamoto; T Mimura; T Sone; T Hirayama; H Tamura; H Yamashita; A Minamoto; H K Mishima
Journal:  Eye (Lond)       Date:  2006-07-07       Impact factor: 3.775

4.  Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab.

Authors:  Marion Funk; Gerald Schmidinger; Noemi Maar; Matthias Bolz; Thomas Benesch; Gerhard J Zlabinger; Ursula M Schmidt-Erfurth
Journal:  Retina       Date:  2010-10       Impact factor: 4.256

Review 5.  Chemokines in vascular remodeling.

Authors:  Andreas Schober; Alma Zernecke
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

6.  Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessment.

Authors:  J Conrath; R Giorgi; D Raccah; B Ridings
Journal:  Eye (Lond)       Date:  2005-03       Impact factor: 3.775

7.  Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.

Authors:  Hideharu Funatsu; Hidetoshi Yamashita; Tomohiro Ikeda; Tatsuya Mimura; Shuichiro Eguchi; Sadao Hori
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

8.  Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

Authors:  Marion Funk; David Karl; Michael Georgopoulos; Thomas Benesch; Stefan Sacu; Kaija Polak; Gerhard J Zlabinger; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2009-10-07       Impact factor: 12.079

9.  Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.

Authors:  Marion Funk; Katharina Kriechbaum; Franz Prager; Thomas Benesch; Michael Georgopoulos; Gerhard J Zlabinger; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-05       Impact factor: 4.799

Review 10.  Cytometric bead array: a multiplexed assay platform with applications in various areas of biology.

Authors:  Edward Morgan; Rudi Varro; Homero Sepulveda; Julia A Ember; John Apgar; Jerry Wilson; Larry Lowe; Roy Chen; Lalita Shivraj; Anissa Agadir; Roberto Campos; David Ernst; Amitabh Gaur
Journal:  Clin Immunol       Date:  2004-03       Impact factor: 3.969

View more
  7 in total

1.  Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study).

Authors:  D S Dhoot; D J Pieramici; M Nasir; A A Castellarin; S Couvillion; R F See; N Steinle; M Bennett; M Rabena; R L Avery
Journal:  Eye (Lond)       Date:  2015-01-30       Impact factor: 3.775

2.  Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration.

Authors:  Thomas Bertelmann; Marta Spychalska; Laura Kohlberger; Stefan Strodthoff; Michael Witteborn; Nadia Kicova; Ulrich Sachs; Sebastian Irle; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-12       Impact factor: 3.117

Review 3.  Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.

Authors:  Bobak Bahrami; Meidong Zhu; Thomas Hong; Andrew Chang
Journal:  Diabetologia       Date:  2016-05-14       Impact factor: 10.122

4.  Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Authors:  Bobak Bahrami; Thomas Hong; Meidong Zhu; Timothy E Schlub; Andrew Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-25       Impact factor: 3.117

Review 5.  Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion.

Authors:  Francisco R Stefanini; Maurício Maia; Paulo Falabella; Marcel Pfister; Moritz Niemeyer; Amir H Kashani; Mark S Humayun; Michael J Koss
Journal:  Clin Ophthalmol       Date:  2014-05-06

6.  Proteomics of vitreous humor of patients with exudative age-related macular degeneration.

Authors:  Michael Janusz Koss; Janosch Hoffmann; Nauke Nguyen; Marcel Pfister; Harald Mischak; William Mullen; Holger Husi; Robert Rejdak; Frank Koch; Joachim Jankowski; Katharina Krueger; Thomas Bertelmann; Julie Klein; Joost P Schanstra; Justyna Siwy
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

7.  Identification of intraocular inflammatory mediators in patients with endophthalmitis.

Authors:  Xiaoli Hao; Changxian Yi; Yuqin Wang; Jin Li; Fang Huang; Liwen He; Wei Chi
Journal:  Mol Vis       Date:  2016-06-02       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.